Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Majid Ghazi

Interventional Pain Medicine Fargo, ND Medical Doctor

NPI 1689691545 CMS profile 122141

2401 41St St S, Fargo, ND 58104

Open in the dashboard

General payments

$6,626

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Majid Ghazi of Fargo, ND is reported in the CMS Open Payments database as having received $6,626 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $794 19
2024 General $1,460 22
2023 General $1,477 13
2022 General $842 13
2021 General $1,285 20
2020 General $196 14
2019 General $573 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Majid Ghazi
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Majid Ghazi were reported at $794. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Majid Ghazi Interventional Pain Medicine median Middle half National median
2019 $573 $684 $216–$2,079 $163
2020 $196 $382 $122–$1,109 $114
2021 $1,285 $552 $167–$1,554 $132
2022 $842 $605 $187–$1,924 $149
2023 $1,477 $671 $195–$1,915 $160
2024 $1,460 $684 $206–$1,837 $164
2025 $794 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,752 25 payments
  2. Boston Scientific Corporation $1,480 23 payments
  3. Relievant Medsystems, Inc. $1,174 5 payments
  4. Medtronic, Inc. $1,095 16 payments
  5. Stimwave Technologies Incorporated $476 6 payments
  6. Medtronic USA, Inc. $130 10 payments
  7. Nevro Corp. $129 3 payments
  8. AbbVie, Inc. $102 6 payments
  9. Curonix LLC $72 3 payments
  10. Amgen Inc. $50 2 payments
  11. Other $166 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,791 101 payments
  2. Travel and Lodging $1,795 5 payments
  3. Education $40 2 payments
Products named General payments · program years 2019–2025
  1. Intracept Pain $1,968 11 payments
  2. Intracept Pain $894 3 payments
  3. Intracept Pain $894 3 payments
  4. Intracept Pain $894 3 payments
  5. Proclaim IPG $787 6 payments
  6. INTELLIS ADAPTIVESTIM $535 6 payments
  7. PROCLAIM $503 10 payments
  8. VANTA ADAPTIVESTIM $319 4 payments
  9. Intracept Intracept Access Instruments (Gen 3)_NMOD $222 5 payments
  10. ETERNA $209 2 payments
  11. Other $1,803 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

210

Median for Pain Management: 951

Drug cost

$730

Median for Pain Management: $26,034

Branded share of claims

83.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 79 $376
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 33 $135
Baclofen Generic 11 $103
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 63 $69
Lorazepam Generic 13 $28
Cephalexin Generic 11 $19

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$123,966

Medicare's payments for the services billed

Medicare patients

404

Average age 74

Services billed

2,033

220 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 35%
Diabetes 30%
Ischemic heart disease 30%
Chronic kidney disease 26%
Heart failure 19%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record